Search

Your search keyword '"de Luca E. V."' showing total 5 results
Start Over Author "de Luca E. V." Publication Year Range Last 10 years
5 results on '"de Luca E. V."'

1. Purple papules during anti-PD1 immunotherapy for metastatic melanoma

Author

De Luca, Erika Valentina, Catapano, Silvia, Del Regno, L., Di Stefani, Alessandro, Peris, Ketty, De Luca E. V., Catapano S., Di Stefani A., Peris K. (ORCID:0000-0002-5237-0463), De Luca, Erika Valentina, Catapano, Silvia, Del Regno, L., Di Stefani, Alessandro, Peris, Ketty, De Luca E. V., Catapano S., Di Stefani A., and Peris K. (ORCID:0000-0002-5237-0463)

Abstract

na

Published
2021

2. 5-aminolaevulinic acid patch photodynamic therapy for the treatment of actinic keratoses: preliminary results from an italian study in the real-life setting

Author

Dattola, Carmelo Alberto, Garcia-Rodrigo, C. G., Tambone, S., Garofalo, V., Lappi, A., De Luca, Erika Valentina, Peris, Ketty, Bianchi, L., Campione, E., Fargnoli, Maria Concetta, Dattola A., de Luca E. V., Peris K. (ORCID:0000-0002-5237-0463), Fargnoli M. C., Dattola, Carmelo Alberto, Garcia-Rodrigo, C. G., Tambone, S., Garofalo, V., Lappi, A., De Luca, Erika Valentina, Peris, Ketty, Bianchi, L., Campione, E., Fargnoli, Maria Concetta, Dattola A., de Luca E. V., Peris K. (ORCID:0000-0002-5237-0463), and Fargnoli M. C.

Abstract

BACKGROUND: Photodynamic therapy (PDT) is recommended for both lesion and field therapy of actinic keratoses (AKs). The 5-amino-laevulinic acid (5-ALA) patch PDT is indicated for the treatment of isolated mild AKs (≤1.8 cm) on the face and bald scalp. It was demonstrated to be effective and safe in clinical trials with a good tolerability profile. METHODS: In this retrospective multicenter real-life study, 33 patients with a total of 99 AKs of the scalp, face, ears, and/or hands and 2 actinic cheilitis were treated with one treatment session of 5-ALA patch PDT with a red light source (total dose of 37 J/cm2). RESULTS: Overall, 12 weeks after treatment, 68/99 (69%) lesions were completely cleared. Complete response was obtained in 82% of AKs on the ears, 78% on the face, 57% on the hands, and 56% on the scalp and in the two actinic cheilitis. The treatment was very effective on grade I AKs, cleared in 87% of the cases and less efficient on grade II–III lesions, cleared in 47% of the cases. 5-ALA patch PDT was well tolerated with a good to excellent cosmetic outcome in 97% of the patients and with 94% of the patients being satisfied or very satisfied with the treatment. CONCLUSIONS: Our results confirm that 5-ALA patch PDT is a good option for AK treatment in clinical practice, it is easy to use, effective and well tolerated even in difficult-to-treat-areas. Moreover, it has an excellent cosmetic outcome.

Published
2020

3. A case of disseminated perforating necrobiosis lipoidica

Author

Gori, Niccolo', Di Stefani, Alessandro, De Luca, Erika Valentina, Peris, Ketty, Gori N., Di Stefani A., De Luca E. V., Peris K. (ORCID:0000-0002-5237-0463), Gori, Niccolo', Di Stefani, Alessandro, De Luca, Erika Valentina, Peris, Ketty, Gori N., Di Stefani A., De Luca E. V., and Peris K. (ORCID:0000-0002-5237-0463)

Abstract

Perforating necrobiosis lipoidica (PNL) is a granulomatous inflammatory skin disease that usually occurs in patients with diabetic. We present a case of a female patient affected by a disseminated form of necrobiosis lipoidica.

Published
2020

4. Photodynamic therapy with 5-aminolevulinate patch for the treatment of superficial basal cell carcinomas

Author

De Luca, Erika Valentina, Tambone, S., Catapano, Silvia, Fossati, Barbara, Peris, Ketty, De Luca E. V., Catapano S., Fossati B., Peris K. (ORCID:0000-0002-5237-0463), De Luca, Erika Valentina, Tambone, S., Catapano, Silvia, Fossati, Barbara, Peris, Ketty, De Luca E. V., Catapano S., Fossati B., and Peris K. (ORCID:0000-0002-5237-0463)

Abstract

5-Aminolevulinate (ALA) patches with red light (630-nm light source and a total light dose of 37 J/cm2) is an effective treatment indicated by food and drug administration (FDA) and european medicines agency (EMA) only for grade I to II actinic keratosis located on the scalp and face. Currently, there are no efficacy data on their use in the treatment of other types of epithelial neoplasms. We analyzed the efficacy of ALA patches in seven superficial basal cell carcinomas (sBCCs) that occurred in four patients. All lesions were treated with topical ALA patches. A complete response of all sBCCs was achieved at week 24 after treatment. Our study suggests that ALA patches for sBCCs have good efficacy rates and excellent safety profile.

Published
2020

5. Efficacy of immune checkpoint inhibitors in different types of melanoma

Author

Rossi, E., Schinzari, Giovanni, Maiorano, Brigida Anna, Indellicati, G., Di Stefani, Alessandro, Pagliara, Monica Maria, Fragomeni, Simona Maria, De Luca, Erika Valentina, Sammarco, M. G., Garganese, Giorgia, Galli, Jacopo, Blasi, Maria Antonietta, Paludetti, Gaetano, Scambia, Giovanni, Peris, Ketty, Tortora, Giampaolo, Schinzari G. (ORCID:0000-0001-6105-7252), Maiorano B. A., Di Stefani A., Pagliara M. M., Fragomeni S. M., De Luca E. V., Garganese G. (ORCID:0000-0002-4209-5285), Galli J. (ORCID:0000-0001-6353-6249), Blasi M. A. (ORCID:0000-0001-7393-7644), Paludetti G. (ORCID:0000-0003-2480-1243), Scambia G. (ORCID:0000-0003-2758-1063), Peris K. (ORCID:0000-0002-5237-0463), Tortora G. (ORCID:0000-0002-1378-4962), Rossi, E., Schinzari, Giovanni, Maiorano, Brigida Anna, Indellicati, G., Di Stefani, Alessandro, Pagliara, Monica Maria, Fragomeni, Simona Maria, De Luca, Erika Valentina, Sammarco, M. G., Garganese, Giorgia, Galli, Jacopo, Blasi, Maria Antonietta, Paludetti, Gaetano, Scambia, Giovanni, Peris, Ketty, Tortora, Giampaolo, Schinzari G. (ORCID:0000-0001-6105-7252), Maiorano B. A., Di Stefani A., Pagliara M. M., Fragomeni S. M., De Luca E. V., Garganese G. (ORCID:0000-0002-4209-5285), Galli J. (ORCID:0000-0001-6353-6249), Blasi M. A. (ORCID:0000-0001-7393-7644), Paludetti G. (ORCID:0000-0003-2480-1243), Scambia G. (ORCID:0000-0003-2758-1063), Peris K. (ORCID:0000-0002-5237-0463), and Tortora G. (ORCID:0000-0002-1378-4962)

Abstract

Immunotherapy can be used for cutaneous, mucosal, uveal and conjunctival melanoma. Nevertheless, we cannot expect the same benefit from checkpoint inhibitors for all the types of melanoma. The different biological features can explain the variable efficacy. The main results obtained with immune checkpoint inhibitors in the various types of melanoma were reviewed.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results